These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12570716)

  • 21. Bisphosphonates and cancer.
    Milner RJ; Farese J; Henry CJ; Selting K; Fan TM; de Lorimier LP
    J Vet Intern Med; 2004; 18(5):597-604. PubMed ID: 15515572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects.
    Teixeira S; Branco L; Fernandes MH; Costa-Rodrigues J
    Mini Rev Med Chem; 2019; 19(12):988-998. PubMed ID: 31020940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How do bisphosphonates inhibit bone metastasis in vivo?
    Fournier PG; Stresing V; Ebetino FH; Clézardin P
    Neoplasia; 2010 Jul; 12(7):571-8. PubMed ID: 20651986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
    Cheng YY; Huang L; Lee KM; Xu JK; Zheng MH; Kumta SM
    Calcif Tissue Int; 2004 Jul; 75(1):71-7. PubMed ID: 15037971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
    Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
    J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of bisphosphonate activity in vitro.
    Mitrofan LM; Auriola S; Mönkkönen H; Mönkkönen J
    Curr Pharm Des; 2010; 16(27):2970-80. PubMed ID: 20722618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effects and anticancer applications of bisphosphonates.
    Morgan G; Lipton A
    Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonates as treatment of bone metastases.
    Holen I; Coleman RE
    Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
    Hughes DE; Wright KR; Uy HL; Sasaki A; Yoneda T; Roodman GD; Mundy GR; Boyce BF
    J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
    Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
    J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined therapies of bone disease with bisphosphonates.
    Syddall SP; Ottewell PD; Holen I
    Curr Pharm Des; 2010; 16(27):2988-97. PubMed ID: 20722617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates in the treatment of bone metastases.
    Finley RS
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):132-8. PubMed ID: 11894024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antitumour effects of bisphosphonates in breast cancer].
    van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW
    Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
    Boissier S; Magnetto S; Frappart L; Cuzin B; Ebetino FH; Delmas PD; Clezardin P
    Cancer Res; 1997 Sep; 57(18):3890-4. PubMed ID: 9307266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitrogen-containing bisphosphonates and cancer immunotherapy.
    Clézardin P; Massaia M
    Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
    Lipton A
    J Support Oncol; 2004; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
    Sahni M; Guenther HL; Fleisch H; Collin P; Martin TJ
    J Clin Invest; 1993 May; 91(5):2004-11. PubMed ID: 8486770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.